Fund Manager Challenges Sinovac Buyout Offers (SVA)

In the days after receiving CFDA (China) approval for its "blockbuster" vaccine, Sinovac Biotech (ticker: SVA) (Interview) received not one but two buyout offers. One investor Heng Ren believes the offers are too low (published with permission):

Is Sinovac's EV71 Vaccine on the Verge of CFDA Approval? $SVA

In late September, I met with Chinese biopharma Sinovac Biotech (ticker: SVA). At the time, management said it expected CFDA approval for its novel EV71 vaccine by early 2016. The same was said on its November earnings call. So did the stock rally this week in anticipation?

Exclusive Interview: Chinese biopharma Sinovac (SVA) Makes a Compelling Case

Last week I met with management of Chinese small-cap Sinovac (ticker: SVA) while they were in New York for the Morgan Stanley Healthcare Conference. We spoke for almost an hour. Here’s the conversation in full (lightly edited):